

People

Appointments

Millennium executive joins 'revolutionary' GPCR drug company

Predix Pharmaceuticals (<http://www.predixpharm.com/>), a specialist producer of drugs that bind to G-Protein Coupled Receptors (GPCRs) has appointed Michael Kauffman as President and CEO. By combining 3D modeling, virtual screening and medicinal chemistry, the company's aim is to slash the quantities of resources needed for drug development and to produce novel therapies more rapidly.

'[Kauffman's] experience and enthusiasm will drive our drug candidates into preclinical and clinical studies, helping us to attain our vision of changing the way drugs are discovered and developed,' stated Chairman Haim Aviv.

Kauffman was equally excited and described his appointment as 'a tremendous opportunity'. He added that he looked forward to working with his new team to bring new therapeutics to the clinic as quickly and as safely as possible. Before joining Predix, Kauffman rose through the senior ranks of Millennium Pharmaceuticals, where he was most recently Vice President of Medicine.

New nasal drug president to address unmet medical needs

Nasal drug delivery technology is the latest challenge for Gordon Brandt, who was named in December 2002 as Executive Vice President of Science and Clinical Development of the Natestech Pharmaceutical Company (<http://www.natestech.com/>).

Chairman, President and CEO Steven C. Quay hopes Brandt's 20 years worth of medical experience will help to expand Natestech's R&D programmes. The company 'will benefit from [his] expertise in clinical programme design and regulatory and medical affairs,' Quay commented.

Brandt, who was most recently Vice President of Clinical and Regulatory Affairs of Sonus Pharmaceuticals, expressed his delight at being chosen for the role. 'Natestech has already proven its ability to develop products that address unmet or poorly met medical needs.' He continued: 'I look forward to contributing to the

company's future success and to the enhancement of shareholder value.'

Molecular Probes appoints new high calibre executives

In a bid to maintain its edge in the competitive life sciences market, Molecular Probes (<http://www.probes.com/>), a manufacturer of fluorescent reagents, has taken on two new executives and promoted one of its own directors. Jack Ball has left his post at Orchid Biosciences to become Chief Commercial Officer. He will now be responsible for sales, marketing, business development and customer support. He is to be joined by Elaine Snowhill, the new Vice President of Program Management.

John White, who has been Molecular Probes' Director of Operations since 2001, has been named as the new Vice President of Operations. President and CEO Anthony Martin said: 'it is a tremendous achievement to attract such high calibre individuals to the senior management team.' He vowed to continue recruiting 'the best possible people to help continue [the company's] rapid growth in sales.'

Senior management changes at Orchid BioSciences

Orchid BioSciences (<http://www.orchid.com>) have announced the resignation of Dale R. Pfost, who has served as President and Chief Executive Officer at Orchid since 1996. The company's Board of Directors has established a search committee to find a replacement for Pfost.

In addition, Orchid announced the resignation of Donald R. Marvin from his position as Senior Vice President and General Manager of Orchid Diagnostics.

George Poste, Chairman of Orchid, said: 'I would like to thank both Dale and Don for their significant contributions, which have helped to provide a solid foundation for our expected robust growth as the leader in profiling genetic uniqueness.' He continued, 'We believe that we have a strong tier of experienced operating managers on board today, and over the coming weeks, I look forward to reporting on advancements in our activities to disposition the Orchid Life Sciences business... and to augment our senior management team.'

Cell Based Delivery name new President and CEO

Thomas P. Mathers has been appointed as President and Chief Executive Officer at Cell Based Delivery (<http://cellbaseddelivery.com>).

Hubert Birner, Chairman of the Board of Directors, said: 'Tom has extensive leadership skills and brings valuable strategic, operational and global business development experience to our team at a time of critical growth and development for the company.'

Mathers has more than 11 years of executive management, sales and marketing experience in the life sciences and medical device industry. Most recently, he was Vice President and General Manager of Cardion Pharmaceuticals, where he had full responsibility for the company's therapeutics development programs for the treatment of autoimmune disorders.

Cell Based Delivery is a biotechnology company that is developing implantable protein delivery systems to treat chronic and life-threatening disease; their initial products target hematological and musculoskeletal disorders.

Graffinity Pharmaceuticals appoints new CEO

Graffinity Pharmaceuticals, a drug discovery and development company and leader in the emerging field of chemical genomics, has announced the appointment of Klaus Schollmeier as Chief Executive Officer as of 1 January 2003.

Chairman of the Supervisory Board, Michael Rheinacker, said: 'With the development of our technology platform now compete and our lead discovery programs showing strong promise, our foremost goal was to select an experienced CEO who could support Graffinity's evolution into a drug discovery and development company.'

Schollmeier, who most recently served as Managing Director of the Healthcare/ Biotechnology Group at ING-BHF Bank, commented on his appointment, 'I consider Graffinity one of the most promising companies in the field of chemical genomics... and anticipate further collaborations as well as taking or own pre-clinical programs forward over the next years.'

People was written by
Peter Chan and Joanne Clough